ST Pharm Co.,Ltd. (KOSDAQ:237690)
163,400
-5,300 (-3.14%)
Apr 29, 2026, 3:30 PM KST
ST Pharm Revenue
In the year 2025, ST Pharm had annual revenue of 331.68B KRW with 21.16% growth. ST Pharm had revenue of 129.10B in the quarter ending December 31, 2025, with 11.55% growth.
Revenue
331.68B
Revenue Growth
+21.16%
P/S Ratio
10.60
Revenue / Employee
506.38M
Employees
655
Market Cap
3,516.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 331.68B | 57.93B | 21.16% |
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| OliX Pharmaceuticals | 14.67B |
| CLASSYS | 336.82B |
| D&D Pharmatech | 4.30B |
| PharmaResearch | 536.29B |